Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Show full item record



Malani , D , Kumar , A , Brück , O , Kontro , M , Yadav , B , Hellesoy , M , Kuusanmäki , H , Dufva , O , Kankainen , M , Eldfors , S , Potdar , S , Saarela , J , Turunen , L , Parsons , A , Västrik , I , Kivinen , K , Saarela , J , Räty , R , Lehto , M , Wolf , M , Gjertsen , B T , Mustjoki , S , Aittokallio , T , Wennerberg , K , Heckman , C A , Kallioniemi , O & Porkka , K 2022 , ' Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia ' , Cancer Discovery , vol. 12 , no. 2 , pp. 388-401 .

Title: Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
Author: Malani, Disha; Kumar, Ashwini; Brück, Oscar; Kontro, Mika; Yadav, Bhagwan; Hellesoy, Monica; Kuusanmäki, Heikki; Dufva, Olli; Kankainen, Matti; Eldfors, Samuli; Potdar, Swapnil; Saarela, Jani; Turunen, Laura; Parsons, Alun; Västrik, Imre; Kivinen, Katja; Saarela, Janna; Räty, Riikka; Lehto, Minna; Wolf, Maija; Gjertsen, Bjorn Tore; Mustjoki, Satu; Aittokallio, Tero; Wennerberg, Krister; Heckman, Caroline A.; Kallioniemi, Olli; Porkka, Kimmo
Contributor organization: Institute for Molecular Medicine Finland
Precision Systems Medicine
Helsinki Institute of Life Science HiLIFE
HUS Comprehensive Cancer Center
Department of Oncology
Hematologian yksikkö
TRIMM - Translational Immunology Research Program
Digital Precision Cancer Medicine (iCAN)
Department of Medicine
Department of Clinical Chemistry and Hematology
Janna Saarela / Principal Investigator
Helsinki Institute for Information Technology
Tero Aittokallio / Principal Investigator
Krister Wennerberg / Principal Investigator
Research Programs Unit
Date: 2022-02
Language: eng
Number of pages: 14
Belongs to series: Cancer Discovery
ISSN: 2159-8274
Abstract: We generated ex vivo drug-response and multiomics profi ling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate for the individually tailored therapies, including 13 complete responses, as well as bridging five patients with AML to allogeneic hematopoietic stem cell transplantation. Data integration across all cases enabled the identifi cation of drug response biomarkers, such as the association of IL15 overexpression with resistance to FLT3 inhibitors. Integration of molecular profi ling and large-scale drug response data across many patients will enable continuous improvement of the FPMTB recommendations, providing a paradigm for individualized implementation of functional precision cancer medicine. SIGNIFICANCE: Oncogenomics data can guide clinical treatment decisions, but often such data are neither actionable nor predictive. Functional ex vivo drug testing contributes signifi cant additional, clinically actionable therapeutic insights for individual patients with AML. Such data can be generated in four days, enabling rapid translation through FPMTB.
3122 Cancers
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
2159_8290.CD_21_0410.full.pdf 15.07Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record